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Abstract
Background: Great strides have been made in the effective treatment of HIV-1 with the development of second-
generation protease inhibitors (PIs) that are effective against historically multi-PI-resistant HIV-1 variants.
Nevertheless, mutation patterns that confer decreasing susceptibility to available PIs continue to arise within the
population. Understanding the phenotypic and genotypic patterns responsible for multi-PI resistance is necessary
for developing PIs that are active against clinically-relevant PI-resistant HIV-1 variants.
Results: In this work, we use globally optimal integer programming-based clustering techniques to elucidate multi-
PI phenotypic resistance patterns using a data set of 398 HIV-1 protease sequences that have each been
phenotyped for susceptibility toward the nine clinically-approved HIV-1 PIs. We validate the information content of
the clusters by evaluating their ability to predict the level of decreased susceptibility to each of the available PIs
using a cross validation procedure. We demonstrate the finding that as a result of phenotypic cross resistance, the
considered clinical HIV-1 protease isolates are confined to ~6% or less of the clinically-relevant phenotypic space.
Clustering and feature selection methods are used to find representative sequences and mutations for major
resistance phenotypes to elucidate their genotypic signatures. We show that phenotypic similarity does not imply
genotypic similarity, that different PI-resistance mutation patterns can give rise to HIV-1 isolates with similar
phenotypic profiles.
Conclusion: Rather than characterizing HIV-1 susceptibility toward each PI individually, our study offers a unique
perspective on the phenomenon of PI class resistance by uncovering major multidrug-resistant phenotypic
patterns and their often diverse genotypic determinants, providing a methodology that can be applied to
understand clinically-relevant phenotypic patterns to aid in the design of novel inhibitors that target other rapidly
evolving molecular targets as well.
Background
For over fifteen years, drug resistance has been a pri-
mary challenge in the effective treatment of HIV, and
our understanding of resistance mechanisms has evolved
along with the virus itself as new therapies have
emerged[1-6]. Thanks to worldwide efforts to tackle
HIV drug resistance, many successful treatment regi-
mens have been developed, including combination
therapies[7,8] such as the Highly Active Anti-Retroviral
Therapy (HAART) regimens[9,10], but treatment
options have been uncertain for patients who fail these
regimens due to the accumulation of drug-resistant
mutations[11]. More recently, in addition to targeting
molecules other than HIV-1 reverse transcriptase (RT)
and protease, second-generation RT and protease inhibi-
tors (PIs) have been developed such that they remain
potent against variants resistant to first-generation inhi-
bitors. Specifically, tipranavir[12] and darunavir[13], the
two PIs most recently approved for clinical use, have
been shown to be potent against viruses harboring mul-
tidrug resistance mutations such as V82A and L90M, in
the cases of both tipranavir and darunavir[13-16], and
V82T or I84V in the case of darunavir[13,16]. However,
even these drugs have been shown to lose potency in
the presence of certain mutations or mutation patterns
[14,17-20]. In fact, the existence of HIV-1 variants
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any medium, provided the original work is properly cited.showing resistance to all clinically-approved inhibitors
highlights the issue of cross resistance, or the existence
of mutation patterns arising from a certain therapeutic
regimen that simultaneously cause resistance to other
d r u g sa sw e l l .C r o s sr e s i s t a n c ea m o n gH I V - 1P I sh a s
been studied[21-26] and reviewed[1,4,27-29] extensively
for over a decade, with several key mutation patterns
thought to confer cross resistance to the vast majority
of PIs. Consequently, one strategy is to take advantage
of the lack of cross resistance when a mutation confers
resistance to one PI but maintains susceptibility to other
PIs. For example, D30N and I50L are associated with
resistance specifically to either nelfinavir and atazanavir,
respectively, but such mutations do not greatly reduce
susceptibility (and I50L actually increases susceptibility)
to other PIs[30-33]. Sequential or simultaneous adminis-
tration of regimens that are each potent against variants
toward which the other fails may be a potential strategy
to prevent drug resistance and treatment failure[34]. In
light of the combinatorial number of both potential
treatment regimens and potential mutation patterns, it
is becoming increasingly important to understand both
the major mutation patterns conferring resistance on
the genotypic level as well as the major phenotypic pat-
terns of cross resistance - or lack thereof - of these
mutation patterns toward the nine clinically-approved
PIs.
Computational analyses have played a key role in
increasing our understanding of the genotypic and phe-
notypic patterns of HIV drug resistance and our ability
to predict drug response phenotype from genotype
[35-37]. The large amount of publicly available data has
greatly facilitated these analyses[35,38]. Several compu-
tational studies have analyzed new or existing data to
identify mutations associated with one or more PI or
RT drugs[39-48]. Some studies have presented longitu-
dinal mutagenetic tree or mutation pathway models for
the temporal appearances and contingencies of such
mutations[49-52]. Others have uncovered pairs or clus-
ters of correlated mutations associated with PI or RT
therapy through direct enumeration, statistical or infor-
mation-theory based methods, clustering, or a combina-
tion of techniques[39,43-46,51,53-63]. One particularly
successful application of computational analysis is the
accurate prediction of drug resistance (phenotype) -
often measured as a fold-change in IC50 of a drug
toward the mutant vs. wild-type - of a target variant
given its amino acid sequence (genotype). Many
approaches have been used to create prediction models,
including regression-based methods[26,64-69], decision
trees[70], and other machine learning methods, includ-
ing artificial neural networks, support vector machines,
and others[67,71-74]. Several studies have also compara-
tively evaluated or combined methods to improve
accuracy[67,72,73,75]. Models have also been created for
predicting drug resistance phenotype[76] and virological
success or failure[77-80] resulting from combination
therapies. In addition to these data-driven approaches,
structure-based approaches for predicting drug response
have also been developed, often in conjunction with the
bioinformatics-based approaches[66,81,82]. Taken
together, the large collection of available predictive
methods still require interpretation and comparison
when making patient treatment decisions[83,84], but
overall they have been valuable tools both for practical
decision-making and for increasing scientific
understanding.
T h em a n yc o m p u t a t i o n a ls t u d i e so fH I Vg e n o t y p e -
phenotype data therefore demonstrate the power of
uncovering patterns in data, with each study providing a
valuable perspective on important features of HIV drug
resistance. However, the vast majority of studies have
offered a perspective at the genotypic level first - that is,
they look for patterns on the genotypic level that corre-
late with phenotypic responses, usually to one drug or
drug regimen at a time, in turn. To our knowledge, a
rigorous cluster-based analysis of genotype-phenotype
data that first uncovers patterns within the complete
phenotypic space and then determines representative
genotypes giving rise to the multidrug response pheno-
types has yet to be done. The goal of this study is there-
fore to provide this unique, simultaneous view into the
existing phenotypic patterns amongst all the HIV-1 PIs,
as such a perspective can provide novel insights into the
major combinations of PIs for which cross resistance
can occur.
In this work, we analyze phenotypic drug resistance
patterns by considering experimental resistance data of
398 clinical isolates of HIV-1 protease measured against
the nine clinically-approved HIV-1 protease inhibitors.
To determine phenotypic drug resistance patterns
toward all nine drugs, a constrained k-medoids cluster-
ing method implemented via integer programming was
employed. Clusters were validated by quantifying their
ability to predict a sequence’s level of resistance toward
o n ed r u gk n o w i n gt h es e q u e n c e ’s level of resistance
toward other drugs. The selection of representative gen-
otypic sequences from each cluster indicated mutations
associated with common patterns of phenotypic resis-
tance and can serve as a “panel” of mutants that collec-
tively represent clinically important variants.
Furthermore, our direct analysis of phenotypic space
allowed us to determine that the virus often utilizes
multiple genotypes to achieve similar phenotypic pat-
terns of multidrug resistance. We also show that certain
drugs show highly correlated antiviral activities, while
other drugs - especially tipranavir - have unique
responses. Finally, information theoretic approaches
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identities within HIV-1 protease that are most informa-
tive for selection into a phenotypic cluster. Taken
together, this work provides a simplified framework for
understanding major drug resistance patterns toward
clinically-approved HIV protease inhibitors and the
mutation patterns that best characterize them.
Methods
Data set
We analyzed 398 HIV-1 isolates in the HIV Drug Resis-
tance Database[38] (HIVDB) for which cell-based in
vitro PI susceptibility testing had been performed by the
PhenoSense (Monogram, South San Francisco, CA)
assay[85]. Susceptibility was quantified by the Mono-
gram-measured fold-change[85], defined as the ratio of
the 50% inhibitory concentration (IC50) of the isolate to
the IC50 of a wild-type control. Only those isolates for
which susceptibility had been tested against all nine
clinically-approved inhibitors were included. The nine
inhibitors considered were amprenavir (APV), atazanavir
(ATV), indinavir (IDV), lopinavir (LPV), nelfinavir
(NFV), ritonavir (RTV), saquinavir (SQV), tipranavir
(TPV), and darunavir (DRV). The data set size was lim-
ited by the availability of isolates tested for DRV sus-
ceptibility. Many clinical isolates contained mixtures at
one or more amino acid positions. Due to the limited
data, mixtures were not excluded from the data set. In
this work, we will refer to clinical isolates as
“sequences,” though we recognize that some contain
mixtures at certain positions.
To estimate the degree to which mutation frequencies
in the genotype/phenotype (n = 398) data set are repre-
sentative of true population frequencies, the frequencies
of non-polymorphic treatment-selected mutations within
non-WT sequences were compared between a larger
genotype-only data set of 12,290 sequences[38] and the
data set used here. Reasonable correlation (Spearman’s r
= 0.88) was found between the data sets (Fig. S1, Addi-
tional File 1).
Fold-change values were log-scaled such that for a
given drug, a constant factor of fold-change is repre-
sented by a constant numerical difference. Because the
relationship between fold-change and clinical response
is different for each drug, scaled values were standar-
dized so that they represent predicted clinical responses,
the phenotype of interest in this work. To do this, the
logarithm base used for the log scaling of each drug was
set to either the Monogram biological cutoff, the geo-
metric mean of the Monogram lower and upper clinical
cutoffs, or the single clinical cutoff provided, depending
on which type of cutoff was available for a particular
drug (Table 1). Monogram biological cutoffs are defined
as the fold-change values below which 99% of the WT
sequences reside, and therefore fold-changes above this
value likely have decreased susceptibility. Monogram
lower and upper clinical cutoffs are fold-change values
at which reduced clinical response and unlikely clinical
response occur for a given drug, respectively. Ritonavir-
boosted cutoff values were used when available. After
log-scaling, scaled resistance values of 1 and 0 qualita-
tively signify decreased susceptibility and susceptibility
equal to WT, respectively, for all drugs. To equalize the
range of variation in the scaled resistances for each drug
and to confine variation to a clinically meaningful range,
we capped the maximal and minimal scaled resistances
of all drugs to the least extreme value of these among
the nine inhibitors – those of DRV (Table 1). The upper
cap of the scaled values (1.83) corresponded to a raw
fold-change value for DRV of 500, the upper-limit value
used when the fold-change toward DRV was greater
than the upper limit of the assay. Sequences with scaled
resistances equal to the capped values are therefore con-
sidered either highly resistant (upper cap) or potentially
hypersusceptible (lower cap). An interpretation of scaled
resistance values is in Table 2.
Clustering
Sequences were clustered based on their drug-resistance
phenotypes, quantified by scaled resistance values. A
globally-optimal constrained k-medoids clustering
approach was implemented via a linear integer program
similar to other variations of integer and mixed-
Table 1 Scaling and capping of raw fold-change values.
Drug Base Max Min
RTV 2.5 7.30 -1.76
NFV 3.6 4.99 -0.94
ATV 5.2** 3.97 -0.73
APV 6.6* 3.17 -0.85
IDV 10** 2.70 -0.52
LPV 22.3* 2.00 -0.52
SQV 5.3* 4.16 -0.97
TPV 4.0* 4.82 -1.16
DRV 30.0* 1.83* -0.47*
The bases used for log scaling each drug were informed by Monogram
biological and clinical cutoffs as described in the text. Unstarred bases are
equal to the available Monogram biological cutoffs; singly-starred bases were
calculated as the geometric mean of lower and upper clinical cutoffs. Double-
starred bases are equal to the single available Monogram clinical cutoff. For
all drugs, scaled values were capped to the least extreme minima and
maxima (those of DRV, shown in bold and starred). Maxima in the table were
generally used when assay upper limits had been reached, representing that
the actual fold resistance was higher than the assay could accurately
determine. The maximum measurable fold-change can vary for a given drug
between isolates, but due to the cap being well below their ranges of
maximum fold-change values, our results are entirely unaffected by variation
for most drugs; the upper fold-change limits for DRV and LPV may have at
times been slightly lower than the upper cap used here, but as a check for
robustness, preliminary results were generated with varying upper caps and
were qualitatively similar to those shown here.
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formulations[86-89]. The k-medoids approach was cho-
sen after exploration of multiple clustering methods (k-
means, hierarchical, and a method based on a tight clus-
tering approach[90]), as it was deterministic, provably
optimal, and allowed for the easy implementation of
hard constraints, which we felt were crucial here for
generating clusters that were phenotypically similar
across all drugs.
The clustering method was as follows: First, each
sequence was assigned a point in a 9-dimensional space
whose coordinates are the scaled resistances toward the
nine inhibitors. From these points, a distance matrix
was generated, in which element dij is the Euclidean 2-
norm distance between the i
th and j
th sequences. The
goal was to select k cluster centers (medoids) from
within the data set and assign each point in the data set
to one of these k medoids such that the sum of the dis-
tances from points to their assigned medoids was
minimized.
Constraints were placed on this optimization to guar-
antee phenotypic similarity within a cluster, as the goal
of this work is for the clusters to represent major phe-
notypic patterns. First, a hard constraint was set to
bound the distance between any cluster member and its
medoid to be less than or equal to a specified value, C.
Secondly, a hard constraint was set to cap the maximum
infinity norm of the distance between any cluster mem-
ber and its medoid to a specified value, C∞. Such a con-
straint prohibits grouping together two sequences that
are highly similar toward 8 drugs but differ qualitatively
in their level of resistance toward only one drug - an
undesirable outcome if we wish for our clusters to high-
light major cross resistance patterns.
k, the number of clusters, is determined by feasibility;
it is the minimum value of clusters for which the con-
straints are satisfied. In this work we use C = 0.95 and
C∞ = 0.58; the value of C = 0.95 occurs roughly at the
“elbow”[91] or “kink”[92] of a plot of the minimum k
needed as a function of tightness (C and C∞)( F i g .S 2 ,
Additional File 1), suggesting that it allows a reasonable
balance between maintaining both a low number of
clusters and adequately tight clusters. A C∞ of 0.58
guarantees that a given cluster members’ scaled resis-
tances toward any given drug cannot vary by more than
2C ∞ = 1.16; there will not be a pair of cluster members
in which one sequence shows no resistance to a given
drug while another shows high levels of resistance (see
Table 2). Higher values of C∞ would make clusters too
diffuse along individual dimensions, preventing their
interpretation as clinically-relevant phenotypic patterns.
Lower values were found to be too restrictive and gener-
ated additional clusters with redundant patterns (data
not shown). To check for robustness of clustering as a
function of these parameters, C and C∞ were each var-
i e di nt u r nu pt o+ / - 0 . 0 5u n i t si ni n c r e m e n t so f0 . 0 2 5 .
Qualitative phenotypic patterns remained very similar,
and pairs of sequences that were clustered together in
the original clustering remained together an average of
71% as these parameters were varied.
Figure S3 (Additional File 1) is a plot of the number
of clusters (k) vs. data set size, using random subsets of
the data. As our data set is currently not large enough
to show robust convergence (k increases with increasing
data set size), the quantitative results that are affected
by data set size are to be considered preliminary; more
data could allow for more robust convergence in future
studies and would increase confidence in the quantita-
tive conclusions.
The integer programming formulation used is shown
in Supplementary Methods (Additional File 1). All inte-
ger programs in this work were implemented using the
GAMS interface (GAMS Development Corporation,
Washington, D.C.) and were solved using CPLEX 11.0.0
(IBM ILOG, Armonk, NY).
Validation
The clustering was validated by its effectiveness (relative
to controls) in predicting the level of drug resistance of
as e q u e n c et oo n ed r u gb a s e do nt h es e q u e n c e ’s levels
of drug resistance toward other drugs, using the follow-
ing n-fold cross-validation procedure[92]:
remove each sequence (in turn) from the data set -
label it sequence “A.”
cluster the remaining sequences using the above
method.
choose one of the nine drugs and eliminate its pheno-
typic data for sequence “A”.
Assign sequence “A” to the cluster to whose centroid
it is closest, based on 8-dimensional distance (i.e.
removing the eliminated drug’s dimension)
Predict the level of drug resistance of sequence A
toward the eliminated drug to equal the cluster cen-
troid’s scaled resistance value for the eliminated drug.
Based on this value, classify sequence A with a resis-
tance score from 0-4 (Table 2).
Table 2 Interpretation of the scaled resistance values
used throughout this work.
Scaled
resistance
Interpretation Resistance
Score
>1.5 Highly resistant 4
1 to 1.5 Decreased susceptibility 3
0.5 to 1 Slightly decreased susceptibility 2
0 to 0.5 No resistance 1
<= 0 No resistance or
hypersusceptibility
0
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correctly classified after leaving out each sequence in
turn was compared to two controls:
Control 1 ("Random Control”): To predict the resis-
tance of a sequence toward a drug, randomly choose a
value from the distribution of scaled resistances in the
data set toward the particular drug, and classify it using
the corresponding resistance score. This control
assumes that the level of resistances between drugs is
not correlated.
Control 2 ("Average Control”): To predict the resis-
tance of a sequence toward a given drug, simply use the
mean of the levels of sequence “A’s” scaled resistances
to the other eight drugs, and classify with the corre-
sponding resistance score. This control assumes that
resistances toward the nine drugs are highly correlated.
Genotypic Analyses
In the absence of amino acid mixtures at positions
within isolates, the genotypic distance between any two
sequences was defined simply as the number of posi-
tions at which their amino acid sequence differed. For
some analyses, all 99 protease positions were considered.
To reduce noise due to polymorphic positions in certain
analyses, only 21 positions that have been associated
with resistance or drug treatment by previous statistical
learning or analysis methods [26,39,48] were considered,
unless otherwise noted: 10, 24, 30, 32, 33, 43, 46, 47, 48,
50, 53, 54, 71, 73, 74, 76, 82, 83, 84, 88, and 90. We
note that there may be unavoidable arbitrariness in the
selection of such a set without considerable initial geno-
typic-phenotypic analysis (which was exactly what we
sought to avoid in this study), and in the course of our
research we tried multiple sets, allowing us to check for
robustness.
To account for mixtures in isolates, the contribution
toward the genotypic difference between two sequences
due to a position, dm, was defined in the general case as
follows:
dm =1− (c/max(s))
where “c” is the number of amino acids that the iso-
lates have in common at that position, and max(s) is the
number of amino acids in the mixture with the greater
number of amino acids at that position. As an example,
if one isolate contained a mixture of leucine and
methionine at a position and another contained only
leucine, then dm for this position would be (1-(1/2)) =
1/2.
Intracluster genotypic or phenotypic variability was
estimated as the average of all the pairwise genotypic or
phenotypic distances. A bootstrapping procedure was
used to generate p-values to assess statistical significance
of either distance for selected clusters. Random clusters
of a size equal to the considered cluster were selected
with replacement from the unclustered data, and the
distance metrics were calculated. This procedure was
repeated 10,000 times to generate distributions for both
genotype and phenotype distances, from which p-values
were calculated. Bootstrap studentized statistics were
obtained by dividing the difference between a value and
the bootstrapped distribution mean by the standard
deviation of the distribution.
From each cluster, representative sequences were
selected. For genotypically diverse clusters, we wished to
select multiple representative sequences from each clus-
ter to highlight genotypic diversity. To that end, con-
strained k-medoids optimizations were run on each
cluster using integer programming; the resulting
medoids became the representative sequences. For each
phenotypic cluster, the minimum value of k was deter-
mined such that all sequences within the cluster would
be within a genotypic distance of ti of at least one
medoid. We used a value of ti = 9 when possible, as it
produced one representative sequence for all but the
most diverse clusters (except for other exceptions noted
below), allowing for easy interpretability. Additionally, at
this k, the sum of the distances between each sequence
and its assigned medoid was minimized. Sequences con-
taining mixtures at any of the 21 positions listed above
were excluded from being representative, as were
sequences with any of the 99 amino acid positions
undefined (only 2 within the data set). With this con-
straint, it becomes possible for phenotypic clusters
(other than single-membered ones containing mixtures
at relevant positions) not to generate any representative
sequences with ti = 9. To account for this, ti was
increased to 10 for clusters 3 and 19 and 10.5 for cluster
10. The integer-programming formulation used here is
shown in Supplementary Methods (Additional File 1).
Sets of sequence positions or amino acid residue iden-
tities most informative of overall cluster assignment or
membership in an individual cluster were identified
according to an incremental mutual information (MI)-
based method described previously (MIST)[93]. Briefly,
the method approximates high-order joint entropies to
determine an optimal small subset of features (e.g., resi-
due positions) that collectively have the highest mutual
information (MI) with a given output (e.g., phenotypic
cluster). These approximated MI values have also been
shown to correlate with classification error and with
exact MI values in analytically solvable systems. First,
the MI between variables of interest was computed,
using the frequencies to estimate probabilities. For each
MI, the bias in the value was estimated by computing
the MI of the pair after randomizing the ordering of the
sequence data for each variable 100 times. Variables
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shuffled MI were considered statistically significant and
included in subsequent steps; remaining positions were
omitted. Sequence positions or binary mutation vari-
ables were then selected incrementally to maximize the
joint-MI (as estimated by MIST) between the set of all
chosen variables and either the cluster assignment or
membership in a specific cluster. Mixtures were not
included in the distributions. Features were added incre-
mentally until all positions or mutations were included,
yielding a full ranking.
Miscellaneous
Data scaling and other matrix manipulations, including
principal component analysis, were done using Matlab
2010a and 2011a (The Mathworks, Natick, MA). Matlab
and Microsoft Excel (Microsoft, Inc., Bellevue, WA)
using VBA were used for figure generation.
Results
Cluster Analysis Reveals Specific Phenotypic Resistance
Patterns Among Clinical Isolates
Globally-optimal k-medoids clustering was used to find
groups of sequences with similar multidrug phenotypes,
using the tightness constraints C and C∞ mentioned in
the Methods to enforce thresholds of phenotypic simi-
larity. The clustering yielded 36 multi-membered clus-
ters, along with 14 outliers. Figure 1 shows the resulting
clusters; each cluster is represented as a row, with each
of the colored boxes within the row representing the
resistance score (Table 2) toward the corresponding
drug of the cluster’s centroid (i.e., average phenotype),
a c c o r d i n gt ot h el e g e n d .A tr i g h t ,r e p r e s e n t a t i v e
sequences are shown for each cluster, with non-WT
amino acid identities shown at selected positions. A list-
ing of mutations at all positions for each representative
sequence is provided as Supplementary Information
(Table S1, Additional File 1). For two clusters (5 and 9),
more than one representative sequence was needed due
to the genotypic diversity.
Generally, the largest clusters were those in which (a)
there was no resistance (or very mild resistance) to any
drug, (b) there was high resistance to all drugs, (c) there
was high resistance toward all drugs except DRV, to
which there was moderate resistance, (d) there was high
resistance toward all drugs except DRV and TPV, (e)
there was resistance toward only NFV and RTV, and (f)
there was high resistance to APV, ATV, NFV, RTV, and
SQV.
The clusters demonstrate that there is often cross
resistance of sequences toward many drugs. Generally,
sequences are most commonly resistant to RTV and
NFV, followed by ATV and SQV, then APV, IND, and
LPV, and finally TPV, and DRV. In general, resistance
to DRV implies resistance to nearly all other drugs, with
a few exceptions: Three clusters showed moderate to
high levels of resistance against all drugs except TPV
(clusters 5, 8, and 12), and two clusters showed moder-
ate to high levels of resistance against all drugs except
SQV (clusters 11 and 15). In both cases, the representa-
tive sequences of the clusters each had at least one
mutation that has been associated with hypersusceptibil-
ity toward the particular drug in a previous study in
which mutations were the independent variables and
fold-change was the dependent variable[26]. These
mutations include L10F, G48V, I50V, I54L, and L76V in
t h ec a s eo ft h ec l u s t e r sw i t hunique susceptibility to
TPV and I47A in the case of the clusters with unique
susceptibility to SQV.
One may ask if grouping 398 sequences into 36 phe-
notypic clusters and 14 outliers shows that HIV is
exploring a large or small part of the available phenoty-
pic space. To address this question, we repeatedly gen-
erated sets of 398 random points within the same nine-
dimensional scaled space of our data set and clustered
them using the same constraints applied to the true
data set. The average minimum number of clusters
needed over 300 trials was 375, with the smallest num-
ber of clusters needed being 357. Clearly, the fact that
only 50 clusters (including outliers) were needed to par-
tition the actual data within the constraints demon-
strates that HIV protease is exploring a very small
portion of possible phenotypic space. In fact, due to the
constraints used in the clustering, the volume of 9-
dimensional phenotypic space occupied by each cluster
must be less than the smaller of either the volume of a
hypersphere of radius C or a hypercube of length 2C∞.
Using our constraint values, the smaller of these is the
former, with a value of ~2.1 volume units. The volume
of clinically-relevant phenotypic space can be calculated
from the maximum and minimum scaled values in
Table 1 to be 1800 volume units. Therefore, only
(2.1*50)/1800 = ~6% of phenotypic space, at best, has
been explored by the considered isolates, compared to
(2.1*375)/1800 = ~44% for a random data set of equal
size.
If a drug is removed from the data set, the minimal
number of clusters needed to represent the phenotypic
diversity must be less than or equal to the minimal
number needed with that drug included. One way to
measure the additional phenotypic diversity provided by
each drug is to remove each drug in turn and re-cluster
using the k-medoids approach under the same distance
constraints. Drugs that, upon removal, greatly reduce
the number of required clusters have phenotypes that
vary somewhat independently from the other drugs.
Drugs that, upon removal, do not greatly reduce the
number of required clusters have phenotypes that vary
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Figure 1 Optimal phenotypic clustering of clinical data set. The optimal set of clusters obtained by using constrained k-medoids clustering
with integer programming. 36 multi-membered clusters and 14 single-member “clusters”, or outliers, were obtained. Each row represents one
cluster. The second column indicates the cluster size. The next 9 columns represent the cluster centroids’ phenotypic drug resistance scores,
colored according to the legend. The columns at right indicate mutations in the sequence selected to represent the cluster at selected positions.
Because isolates with mixtures at any of the specified positions were not allowed to represent a cluster, certain single-membered clusters do not
have a representative “sequence.” The representative sequences chosen for clusters 29, 31, 34, and 36 show no mutations at the positions listed
here, but they have substitutions at other positions (Table S1, Additional File 1).
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Page 7 of 19predictably with (though not necessarily in a correlated
manner with) the remaining drugs. When this analysis
was carried out, it was found that removal of TPV
reduced the number of needed clusters by the most
(from 50 to 31), suggesting that TPV’s response toward
sequences varies somewhat independently from other
drugs. In other words, TPV might show varied, graded
responses toward certain groups of sequences toward
which other drugs show relatively constant responses.
Removal of ATV, SQV, or APV also reduced the num-
ber of needed clusters by over 10 (from 50 to 37, 38,
and 38, respectively). Removal of LPV, DRV, NFV, RTV,
or IDV reduced the number of required clusters the
least (to 44, 44, 43, 43, and 41, respectively) suggesting
that their scaled resistances either vary predictably with
those of the other drugs or do not vary appreciably in
general.
Phenotypic clustering allows for potentially improved
prediction of unknown drug phenotypes given
phenotypic information for other drugs
Our results indicate that a small portion of the full
phenotypic space has been explored by the virus,
assuming a representative data set; consequently, one
may be able to successfully predict resistance to a
given inhibitor given resistance data toward other inhi-
bitors, without knowing any genotypic information. To
test this hypothesis, we used a cross-validation proce-
dure in which each sequence from the data set was
removed in turn and the sequence’s resistance toward
each drug was estimated based on a clustering assign-
ment using the other eight resistance phenotypes (see
Methods). Pairs of sequences that were clustered
together in the original clustering remained together
an average of 99.3% of the time across all n runs of
the validation, not counting runs in which a member
of the pair was excluded in turn, demonstrating the
stability of the clustering during the cross-validation
procedure. The results of the cluster-based prediction
are summarized in Table 3.
Two controls were used for comparison and are
described in the Methods. Control 1 ("Random”), which
randomly reported a value from the distribution of
scaled resistances in the data set toward the particular
drug, was able to correctly categorize resistance 21%-
36% of the time, depending on the drug. The RMSE’so f
the actual scaled resistance values were often over a
whole unit away, meaning that it would often predict no
resistance when there was in fact resistance, and vice
versa. NFV and RTV were classified correctly most
often; the clustering suggests that this may be because
they were more likely to exhibit either no resistance or
complete resistance, providing a less graded distribution
overall from which to sample.
Control 2 ("Average”), which guessed the “unknown”
phenotype to be the average of the other 8 known phe-
notypes for the isolate, performed much better overall
than Control 1, categorizing resistance correctly for
more than half of the sequences for ATV, APV, IND,
LPV, and SQV. Its strong performance is additional evi-
dence for the high level of both correlation between
drug responses and cross resistance. Performance was
worse for (1) NFV and RTV, which are often inactive to
viruses toward which other drugs are effective, as Figure
1 indicates, (2) DRV, which, according to Figure 1, often
remains effective toward viruses resistant to other drugs,
Table 3 Cluster-based prediction of phenotypic resistance relative to controls.
With all data RTV NFV ATV APV IDV LPV SQV TPV DRV
CTL1 (Random) % correct 35 36 29 21 22 26 29 31 29
CTL1 (Random) RMSE 1.34 1.13 1.21 1.2 1.05 1.01 1.26 0.98 0.76
CTL2 (Average) % correct 46 43 62 60 62 56 57 47 34
CTL2 (Average) RMSE 0.60 0.54 0.36 0.34 0.26 0.28 0.41 0.67 0.67
Cluster-based % correct 81 75 74 70 63 67 65 50 67
Cluster-based RMSE 0.35 0.34 0.38 0.33 0.29 0.25 0.50 0.71 0.29
Without nonresistant clusters RTV NFV ATV APV IDV LPV SQV TPV DRV
CTL1 (Random) % correct 78 66 45 27 22 29 34 18 29
CTL1 (Random) RMSE 0.54 0.68 0.84 0.97 0.86 0.83 1.06 1.00 0.74
CTL2 (Average) % correct 28 32 49 51 52 43 46 28 11
CTL2 (Average) RMSE 0.74 0.64 0.45 0.41 0.32 0.34 0.51 0.84 0.84
Cluster-based % correct 89 82 73 62 55 58 60 34 56
Cluster-based RMSE 0.26 0.23 0.38 0.40 0.36 0.31 0.62 0.89 0.36
Percent of viruses whose resistance score toward each drug was correctly classified ("% correct”), as well as the RMS error (in scaled resistance units) over all
sequences of the phenotypic difference between predicted and actual phenotype ("RMSE”) using the two controls described in the text ("CTL1 (Random)” and
“CTL2 (Average)” and the cluster-based prediction. The top panel presents results using all 398 sequences, and the bottom panel shows results after removing
the two clusters showing little or no phenotypic resistance to any drug.
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Page 8 of 19and (3) TPV, which, as shown above, has less phenoty-
pic similarity to other drugs.
Compared to either control, the cluster-based predic-
tion correctly classified a higher percentage of viruses
for every drug, although the improvement over Control
2 was modest in some cases, with the RMSE’sb e i n g
marginally higher in some cases as well, suggesting that
when the cluster-based classification was incorrect, it
was quite different. The improvement in classification
was largest for NFV, RTV, and DRV. Classification rates
overall were well over 50% correct with RMS errors
being fairly small (generally <= 0.5 units away). The
notable exception is TPV, again supporting TPV’s
uniqueness.
The relatively large number of sequences susceptible
to all drugs in our data set might bias the prediction
accuracy of certain methods to be higher than what
w o u l db ee x p e c t e df r o mad a t as e tt h a tc o n t a i n e da
more even distribution of all multidrug phenotypes. To
control for this, we redid the above analysis after having
left out the sequences corresponding to the two clusters
shown in Figure 1 that show no or very little resistance
to all nine drugs (clusters 36 and 34, with 77 and 71
members, respectively). Not surprisingly, Control 1 per-
forms much better with RTV and NFV, as now, nearly
all sequences in the data set are resistant to either drug.
Also unsurprisingly, Control 2 performs worse because
the two clusters that were removed contained sequences
whose responses to all drugs were highly correlated.
The cluster-based classifier still has the highest classifi-
cation accuracy, but again, the RMSE values were some-
times greater than those for Control 2. Nevertheless,
these results show that an understanding of major phe-
notypic resistance patterns can allow for reasonable pre-
diction of a sequence’s resistance toward one drug given
resistance information toward other drugs, and the
strong performance of the controls under certain cir-
cumstances further highlights the underlying structure
in the resistance patterns.
The accumulation of HIV protease mutations results in a
“path” in phenotypic space
Principal component analysis (PCA) was used to project
the nine-dimensional, columnwise-centered drug-resis-
tance phenotypes of all sequences onto the two dimen-
sions along which there is most variation. Figure 2 is a
plot of the sequences in this two-dimensional space,
colored by the total number of amino acid differences
from consensus-B wild type protease (considering all 99
amino acid positions). The first two principal compo-
nents are able to capture approximately 90% of the var-
iation in the data, again suggesting that there are large
correlations between drug responses toward the
sequences. As indicated in Table 4, the first principal
component indicates resistance toward all drugs (i.e.,
complete cross resistance), with slightly less resistance
toward TPV and DRV, relative to their means. The sec-
ond principal component indicates resistance toward
Figure 2 Projection of the phenotypic data onto its first and second principal components. Points are colored by the total number of
amino acid substitutions relative to the consensus B WT sequence, according to the scale at right; a mixture at a position (including those
containing the WT amino acid) is counted as one substitution. The phenotypes and genotypes of selected sequences are indicated. The 9-digit
shorthand phenotypic code used to describe the sequences indicates the resistance score (Table 2) to each of the 9 PIs in the order shown in
Fig. 1: RTV, NFV, ATV, APV, IDV, LPV, SQV, TPV, DRV. All “outlying” sequences are fully listed in Supplementary Information (Fig. S4, Additional File
1).
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Page 9 of 19NFV and RTV, less resistance to ATV, SQV, and IDV,
and low resistance or even increased susceptibility
toward APV, LPV, DRV, and especially TPV, relative to
each drug’s mean resistance value.
Interestingly, the points in Figure 2 form a “path”
through phenotypic space. Such “horseshoe"-shaped
paths are often indicative of a non-linear ordering or
underlying gradient in the data[94]. Here, the path
clearly tracks the genotypic mutations accrued by the
sequences. Sequences with few mutations appear to
have resistance toward NFV, RTV, ATV, SQV, and IDV,
but little resistance to APV, LPV, DRV, or TPV (i.e., the
phenotypic path “veers upward” in the principal compo-
nent space), while sequences with many mutations are
resistant to all drugs (far right in the principal compo-
nent space). Three sequences along the path are selected
in Figure 2 and their corresponding scaled phenotypes
and genotypes are listed to the right of the plot. The
point selected on the intermediate portion of the path
represents a sequence that includes the mutations M46I
and L90M, which have been shown to be highly corre-
lated[59] and to be associated with resistance to NFV,
IDV, and RTV, and other drugs to a lesser extent[56].
The point selected at the right end of the path repre-
sents a sequence that shows at least moderate resistance
to all drugs, and includes the mutations V82T, I84V
associated with resistance to TPV[18], and L33F, I47V,
and I54M, associated with resistance to both TPV[18]
and DRV[20], in addition to containing mutations that
harbor resistance toward first-generation drugs.
A saw h o l e ,F i g u r e2s u p p o r t st h eh i s t o r i c a l“path” of
drug development, in that it is relatively easy to become
resistant to first-generation drugs with relatively few
mutations (RTV, NFV, SQV, etc.), but many
accumulated mutations appear to be necessary to confer
resistance to the newer drugs, such as darunavir[16,19].
Whether or not this pathway is due to history and treat-
ment regimens or whether it is a fundamental conse-
quence of the structural features of the drugs and the
viable evolutionary space of HIV-1 protease requires
further study.
A handful of sequences lie “off” the pathway. Three
such sequences are indicated in Figure 2, and several
more are listed in Fig. S4 (Additional file 1). The top
and bottom sequences indicated in Figure 2 are both
uniquely susceptible to SQV and have the mutation
V82L which has been associated with increased SQV
susceptibility[26]. The middle sequence shows low levels
of resistance across all nine drugs. All three of these
sequences fall off the pathway because of their non-neg-
ligible levels of resistance toward one or more second-
generation drugs while maintaining susceptibility to one
or more first-generation drugs. Additional outliers are
shown in the Supplementary Information (Additional
File 1).
Phenotypic Similarity Does Not Imply Genotypic Similarity
Figure 3a is a plot of scaled phenotypic distance vs. gen-
otypic distance for all (398*397)/2 = 79003 sequence
pairs, using all amino acid positions to compute genoty-
pic distances. Not surprisingly, sequences that are geno-
typically similar are phenotypically similar; there are no
points in the upper-left corner of the plot. However,
there are many sequences that are very different genoty-
pically and yet have similar scaled resistance phenotypes
(there are many points in the lower-right corner), sug-
gesting that HIV-1 may arrive at the same multidrug
resistance phenotype via rather varied genotypes. Figure
3b is again a plot of all pairwise phenotypic distances vs.
their genotypic distances, except now, only the resis-
tance-associated positions specified in the Methods have
been included in calculating genotypic distance. While
the upper left corner of this plot is still sparse, this plot
indicates that polymorphic or accessory positions not
considered in genotypic distance may still affect resis-
tance profiles in the absence of mutations commonly
associated with drug resistance (i.e. there are pairs of
sequences with a genotypic distance of zero in Figure 3b
but a moderate phenotypic distance). Again, there are
still sequences that are genotypically very different yet
show similar resistance phenotypes.
Mutations from two sample pairs of sequences from
the lower-right quadrant of each figure are shown. In
Figure 3b only the mutations contributing to the geno-
typic distance are shown. As can be seen, very different
genotypes can generate similar resistance patterns. For
example, the sequences shown in the lower box at the
right of Figure 3a show high levels of resistance toward
Table 4 The nine principal components in scaled
phenotypic space.
Principal
Component
123456789
Ritonavir 0.39 0.35 0.60 -0.16 0.30 -0.37 -0.32 -0.05 -0.07
Nelfinavir 0.36 0.33 0.22 -0.05 -0.10 0.31 0.75 -0.11 0.17
Atazanavir 0.39 0.12 -0.10 0.23 0.01 0.72 -0.49 -0.12 -0.04
Amprenavir 0.36 -0.29 -0.17 -0.49 0.29 0.13 0.07 0.63 -0.12
Indinavir 0.33 0.04 -0.14 -0.02 -0.62 -0.23 0.02 -0.02 -0.65
Lopinavir 0.31 -0.12 -0.18 -0.33 -0.43 -0.19 -0.21 -0.15 0.67
Saquinavir 0.38 0.15 -0.48 0.58 0.29 -0.38 0.11 0.14 0.14
Tipranavir 0.23 -0.71 0.48 0.43 -0.12 -0.02 0.07 0.07 0.07
Darunavir 0.19 -0.37 -0.21 -0.23 0.39 -0.04 0.12 -0.72 -0.21
Percent
Variance (%)
83.7 6.0 3.1 2.7 1.6 1.0 1.0 0.6 0.3
The first two principal components together capture approximately 90% of
the variance in the data and represent development of high resistance toward
all drugs and development of high resistance to NFV and RTV with increasing
resistance toward ATV, SQV and IDV, respectively.
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Page 10 of 19all drugs; each sequence has a subset of documented
drug resistance mutations, such as V32I, L33F, M46I,
I47V, F53L, G73S, V82A, and L90M in the case of the
first sequence and M46L, I54V, V82F, and I84V in the
case of the second sequence, but the sequences have
few mutations in common (K20R, E35D, M36I, L63P,
A71V, and I93L), most of which are considered highly
polymorphic accessory mutations[95]. The variety of
mutations through which the protease is able to achieve
similar multidrug clinical phenotypes demonstrates that
phenotypic similarity does not imply genotypic
similarity. Recall here that two sequences that are both
sufficiently above the clinical fold-change cutoff for
resistance for a given drug are both considered phenoty-
pically identical toward that drug, due to the capping of
scaled resistance values above a threshold. Therefore,
while they are phenotypically similar from a clinical per-
spective, they may possess quite different (but both
large enough to be considered resistant) raw fold-change
values toward a given drug.
Another way to understand the genotypic variation for
a given phenotypic pattern is to analyze the genotypic
Figure 3 Pairwise phenotypic distance vs. pairwise genotypic distance for all pairs of sequences. (a) Scaled phenotypic distance vs.
genotypic distance with all positions considered in calculating genotypic distance and (b) with only resistance-associated positions used in
calculating genotypic distance. The density of points is colored according to the scale at right. The sequence pairs corresponding to two points
are indicated. The 9-digit shorthand used to describe the two pairs of sequences indicates the resistance score (Table 2) to the PIs in the order
used in Fig. 1: RTV, NFV, ATV, APV, IDV, LPV, SQV, TPV, DRV.
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dual phenotypic cluster obtained in the above analysis,
we used a k-medoids approach to identify representative
genotypes for that cluster. Through constraints, a more
genotypically diverse phenotypic cluster would require
more sequences to represent it. Figure 1 shows the
representative sequences chosen for all phenotypic clus-
ters. As can be seen, two clusters (5 and 9), even though
they are of similar sizes to others, require multiple
representative genotypic sequences. Multiple representa-
tive sequences for a cluster suggest multiple genotypic
paths to the phenotype.
To quantify phenotypic and genotypic diversity within
clusters, resampling was carried within each cluster as
described in the Methods. Table 5 summarizes the
results for all clusters with more than 6 members. The
p-values for intracluster phenotypic distance ("P Pheno”)
show significantly low variation, but hard constraints in
the clustering enforced phenotypic similarity so this low
variation is by design. It is also not surprising that the
genotypes of non-resistant clusters are also statistically
similar (bootstrap studentized statistics for clusters 34
and 36 are -11.3 and -13.3), as none of these sequences
would be expected to bear a resistance-associated muta-
tion, so they should all effectively be “wild-type”.H o w -
ever, among multidrug resistant phenotypes, there is
either no more or no less genotypic variation between
members within a cluster than there is between any two
random sequences in the data set (insignificant
“P_Geno” values), or there is more genotypic variation
than would be expected by random sampling in the
cases of clusters 5 and 7 (P_Geno < 0.01; bootstrap stu-
dentized statistics are 2.26 and 2.16). Furthermore, on
average, pairs of sequences from the same cluster gener-
ally share less than 50% of their mutations (using resis-
tance-associated positions listed in the Methods); the
one exception is the cluster containing sequences resis-
tant to all drugs (cluster 1), whose members share 54%
of their mutations on average; indeed the average intra-
cluster genotypic distance for this cluster is in some
cases less than that for clusters containing fewer muta-
tions on average, suggesting that a higher number of
mutations may not mean greater genotypic variation,
and also indicating that the most highly resistant
sequences might need to have some “key” mutations in
common. When removing from the data set one from
each pair of 28 sequences from the same patient at two
different time points and reclustering, the most highly
resistant cluster still had >50% shared mutations on
average and a lower intra-cluster genotypic distance
than some other resistant clusters, although it now
required two representative sequences, suggesting that
s o m e-b u tn o ta l l-o ft h i ss i m i l a r i t ym a yb ed u et o
including data at different time points from the same
patient. This idea is further addressed in the Discussion.
N e v e r t h e l e s s ,w h i l eal a r g e rd a t as e tw o u l da l l o wf o ra
Table 5 Statistical analysis of phenotypic and genotypic variability within each cluster containing 6 or more members.
NUM Phenotype #Seqs Intra_Pheno P_Pheno Intra_Geno P_Geno Avg_Muts Shared_Muts Shan._Ent.
1 444444444 15 0.69 0 6.15 0.47 9.1 4.95 14.52
2 444444442 28 0.56 0 7.31 0.02 8.3 3.4 18.78
4 444433433 10 0.64 0 7.83 0.05 8.7 3.84 18.33
5 444444413 6 0.63 2E-04 9.63 0.001 9.8 3.9 18.33
6 444433342 6 0.81 7E-04 7.07 0.27 7.7 3.33 13.74
7 444443422 31 0.8 0 7.5 0.008 7 2.43 19
9 444433422 7 0.63 0 8.31 0.04 8.6 3.79 16.91
12 444423402 6 0.65 2E-04 7.82 0.12 7.8 3.04 15.73
14 444232421 10 0.91 1E-04 6.61 0.34 5.9 2.19 14.14
16 444233401 8 0.82 1E-04 6.54 0.38 6.4 2.36 13.84
20 444222221 8 1.01 2E-04 6.18 0.49 5.2 1.41 13.84
26 442121211 13 0.85 0 4.11 0.05 3 0.71 9.88
29 321111111 9 0.8 0 2.38 7E-03 1.3 0.07 5.64
34 111010110 71 0.65 0 0.94 0 0.5 0.03 2.95
35 301000011 6 0.64 2E-04 0.67 3E-03 1 0.67 1.48
36 000000000 77 0.6 0 0.24 0 0.1 0 0.89
“Phenotype” is the nine-digit shorthand describing the binned level of resistance of the cluster centroid toward each of the nine drugs (see Fig. 1 for drug order).
“Intra Pheno” is the average intra-cluster phenotypic distance (in scaled resistance unites). “P pheno” are p-values for intra-cluster phenotypic distance. A p-value
of 0 indicates that a more extreme distance was not sampled in 10,000 trials. Analogous headings are shown for genotypic distance as well; genotypic distance
was defined using the list of non-polymorphic positions in the Methods. “Avg Muts” is the average number of mutations at non-polymorphic positions for
sequences within the cluster. “Shared Muts” is the average number of shared mutations between all pairs within a cluster. Shan. Ent. is the computed Shannon
Entopy (in bits) for the cluster, adding up the entropies at each non-polymorphic position.
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within a cluster when computing p-values and for the
exclusion of data from the same patients at multiple
time points, thus allowing for fairer comparisons, this
simple analysis suggests again that in general, phenoty-
pic similarity does not imply genotypic similarity, and
certain multidrug phenotypes may be achieved by more
varied genotypes than others.
Feature selection uncovers important positions and
mutations for cluster assignment
Finally, we sought to rigorously determine sets of amino
acid positions and mutations that were most informative
of membership in the phenotypic clusters. Figure 4a
shows the results of greedily selecting one position at a
time such that at each step (going left to right), the
(approximate) mutual information (MI) between the
chosen set of features and the cluster assignment is
maximized. Only those positions that had significant MI
with the output are included. The red bars indicate the
MI between an individual position and the cluster
assignment, with the yellow star indicating the threshold
for statistical significance (p = 0.01). The blue bars indi-
cate the joint MI between the subset selected thus far
and the cluster assignment. Note that positions are not
strictly selected in decreasing order of individual MI.
Because mutations at certain positions may be highly
coupled with positions already in the feature set, less
individually informative positions may contribute to a
more informative set of positions. This technique there-
fore chooses highly non-redundant features that are still
informative of the output. Finally, the black bar shows
the total information content of the output, the cluster
assignments.
Figure 4a indicates that several positions have signifi-
cant MI with the final cluster assignment, especially
positions 54, 90, 84, 46, 33, 20, 82, 32, 88, and 71. This
is consistent with findings that these positions are
known to mutate in the presence of drug resistance,
either as primary or accessory mutations[4,47,48]. Col-
lectively, these positions are computed to be nearly as
informative of ultimate cluster assignments as the entire
set of positions considered. The fact that position 54 is
chosen as the most informative feature is not surprising,
given the large range of drug-resistant mutations com-
monly found at this position and their varied effects
toward certain drugs as either primary or secondary
mutations; I54L, I54M, I54V, etc., can have different
consequences toward drugs such as TPV, DRV, and
APV[4,95] Also interesting is the redundancy of position
10 and, to a lesser extent, position 71; although position
10 has a high mutual information with the cluster out-
put, it does not provide additional information once the
identities at the ten positions listed above are known.
Position 71 provides some additional information but is
also quite redundant. These results are consistent with
the amino acids at positions 10 and 71 both being
highly correlated with those at other positions such as
54, 90, 82, 84, and others[54,55,59], as it is believed that
mutations at these positions can be compensatory in
nature[54,55,96]. Finally, one should note that the
approximate joint MI calculated between all of the posi-
tions and the output is still quite less than the true
information content of the output, suggesting that
amino acids considered at all positions still may not
result in perfect prediction of these output data. This is
likely due to the true importance of higher-order infor-
mation (i.e. patterns of three or more amino acids
occurring together) in contributing to ultimate pheno-
types - the importance of which has been noted pre-
viously[61] - as well as noise in the measurement and
clustering of the phenotypic data, thus highlighting the
inherent difficulty of accurately predicting phenotype
from genotype in these complex systems. The limita-
tions of the second-order approximation also result in
the approximated total joint mutual information
between the features and the output (blue bars) failing
to be monotonically increasing as they would be were
an exact calculation feasible, again highlighting the com-
plex relationship between various protease positions and
phenotype.
Figure 4b shows the specific amino acid identities cal-
culated to be most informative of ultimate cluster
assignment. Here, key resistance mutations are chosen
that cause broad resistance to many of the older drugs,
such as L90M and I84V. At positions that can bear sev-
eral identities, such as 54, 46, and 82, the selection of
the wild type amino acid suggests the importance of the
lack of any mutation at these positions in determining
cluster assignment.
Figures 4c and 4d show sample results for mutations
that are informative of assignment into specific clusters
- cluster 1 (c), the most resistant cluster, and cluster 36
(d), the completely nonresistant cluster. All other results
for clusters with 8+ members are shown in Figure S5
(Additional File 1). Figure 4c indicates that the amino
acid identities most informative of membership into the
“most” resistant cluster include several mutations that
have been associated with resistance to DRV[97] includ-
ing V11I, L33F, V32I, L89V, and G73S, as well as muta-
tions such as I84V and L90M that are associated with
broad cross resistance toward other PIs.
Finally, many of the informative residues in the non-
resistant cluster (Figure 4d) are actually wild type amino
acids. This suggests that the lack of mutations at these
positions correlates with low levels of resistance. Addi-
tionally, several mutations listed are at accessory posi-
t i o n ss u c ha s1 0 ,6 3a n d3 6 ,s u g g e s t i n gt h a tm u t a t i o n s
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Figure 4 Stepwise selection of HIV-1 protease positions and mutations that are important for cluster assignment. (a) Stepwise selection
of HIV-1 protease positions (from left to right) such that at each step, the mutual information between amino acids at positions selected so far
and the cluster assignment is maximized. Red bars indicate (bias-adjusted) MI between each individual position and cluster assignment. ‘x’s’ are
the standard deviation of MI estimation for two independent variables, and asterisks indicate the threshold for statistical significance (p=0.01).
Blue bars are the estimated joint MI between the subset chosen and the cluster assignment. The black bar indicates the total information
content of the cluster assignments. (b) Stepwise selection of the most informative amino acid identities at specific positions for assignment into
phenotypic clusters. (c) and (d): Stepwise selection of particular amino acid identities whose collective presence or absence are maximally
informative of membership specifically into cluster 1 (c) and cluster 36 (d).
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Page 14 of 19at these positions are reasonable markers for “any” resis-
tance in general. It is importa n tt on o t et h a tw h i l et h i s
method highlights which mutations are most informa-
tive of cluster assignment, it does not identify whether it
is the presence or the absence of the mutation that is
associated with cluster membership.
Discussion
This study highlighted major patterns of phenotypic
resistance across all nine clinically-approved HIV-1 PIs.
Cluster analysis yielded several phenotypic patterns,
including clusters showing resistance to all drugs, all but
o n es p e c i f i cd r u g( s u c ha sT P V ,S Q V ,o rD R V ) ,al a r g e
subset of drugs, a small subset of drugs, and only one
drug (such as NFV or ATV). Through choosing repre-
sentative sequences for each phenotypic pattern, we
have corroborated previously reviewed observations
[4,27,29] that mutations such as L33F, V82A, I84V, and
L90M are associated with broad cross resistance, while
others, such as D30N and I50L are associated with resis-
tance to only one drug and still others such as I47A and
I54L are linked with hypersusceptibility toward a given
drug. While we have uncovered a variety of phenotypic
patterns, not every possible resistance pattern was
sampled, suggesting that cross resistance and other fac-
tors cause highly correlated drug responses, assuming
our data set is representative. Indeed, our considered
isolates occupy only a small portion (~6%) of the avail-
able, clinically-relevant phenotypic space. For example,
no cluster shows a moderate or high level of resistance
toward DRV without resistance to several other drugs,
including APV and LPV. Whether this result is due to
patient treatment histories or the intrinsic properties of
the drug–protease interactions requires further study. If
the latter is at least partly the case, it corroborates the
observation that DRV may have a higher genetic barrier
to resistance[16,19].
TPV’s response toward sequences often shows little
relationship to other drugs’ responses. The relative lack
of cross resistance to TPV may make it particularly use-
ful[14] in conjunction with other inhibitors to “cover”
the mutation space of the virus. TPV’sd i f f e r i n g
response profile may follow from its unique structural
characteristics. It is the only clinically-approved inhibitor
that does not use a water molecule to mediate hydrogen
bonds with the flap regions of the protease, suggesting
the importance of developing structurally diverse drug
molecules toward a target as a strategy to combat resis-
tance[98].
The representative sequences of four clusters (29, 31,
34, and 36) had no mutations at the 21 positions con-
sidered in computing genotypic distance for this pur-
pose, and yet their phenotypes were not identical on
average. This suggests a potential role for mutations at
other positions that may not be associated with primary
drug resistance. A rigorous study that analyzes the dif-
ferences in mutation frequencies in such clusters and
considers their impacts on the susceptibilities of indivi-
dual cluster members, while beyond the scope of the
current work, would be interesting potential future
work, especially when more data are available.
We demonstrated that phenotypic clustering may
allow for prediction of resistance to a particular drug
based only on resistance information toward other drugs
and no genotypic information. While our goal was not
to develop a prediction method that is superior to the
available genotypic-based methods specific to each drug,
especially as it may be rare to have multidrug phenoty-
pic data available, it is interesting to assess how well our
“genotype-blind” method performs when compared to
genotype-based methods. Rigorous comparisons to
mean standard error values in other studies are difficult
due to different scaling and capping procedures used
here for phenotypic standardization. Nevertheless, some
studies used a Pearson correlation coefficient (R)
between predicted and actual log-fold-change as a mea-
sure of accuracy. R values for PIs available at the time
of selected studies ranged from 0.85-0.97[69], 0.65-0.93
(across multiple methods)[67], and 0.78-0.89[64]. From
the cross-validation procedure used to generate Table 3,
our “genotype-blind” method gave R-values ranging
from 0.84-0.94 using all 398 data set members, with the
exception of TPV, although these numbers may be arti-
ficially high due to our capping of extreme values. Pre-
dictions of resistance to TPV had an R value of only
0.45, consistent with the observed difficulty in predicting
TPV resistance based on the phenotypes shown toward
other drugs. Finally, our reported classification accura-
cies are lower than those reported for genotype-based
predictions, but this is partly because we use five cate-
gories as opposed to the binary or 3-way classifications
commonly used. If we adopt a naive binary classification
scheme (scaled resistance < 1.0 is not resistant; scaled
resistance >= 1.0 is resistant), our cluster-based classifi-
cation accuracies using the n-fold cross validation pro-
cedure for the entire data set range from 85%-95%
excluding TPV(79%), compared with 85%-95% for binary
classification schemes reported in the literature
[65,72,74] (TPV and DRV were not part of these stu-
dies). It is interesting to note that while not the major
goal of our paper, we have shown that with the excep-
tion of TPV, it may be possible to approach comparable
drug resistance prediction accuracy without any genoty-
pic information; this level of accuracy demonstrates the
restricted phenotypic space occupied by the virus.
Our analysis was limited by the number of accessible
isolates that have each undergone phenotypic resistance
testing against all nine inhibitors. A large priority for
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Page 15 of 19future work is acquiring enough data such that the
number of clusters is robust to the data set size such
that one could be confident that all or nearly all pheno-
typic patterns have been sampled. One strategy is to
pool isolates phenotyped by different assays to bolster
the amount of data; indeed, a preliminary clustering was
carried out in which the data analyzed here were com-
bined with 196 isolates phenotyped using the Antiviro-
gram (Virco, Mechelin, Belgium)[99] assay, but
differences between the assays may have subtle but
important effects on the interpretation of scaled resis-
tance values, even when using cutoffs specific to each
assay, creating potential artifacts in the clustering (we
obtained 67 clusters with the combined data set, a larger
number than expected given the pattern shown in Fig.
S3). More data would allow for larger cluster sizes in
general, and therefore a higher confidence in associating
certain genotypic features with cluster assignments; one
could also look for differences in phenotypes between
virus subtypes if such data were concurrently available.
Additionally, more data may allow for cluster sizes to
accurately represent the relative frequencies of pheno-
types within the population and would allow us to
exclude isolates containing mixtures at key positions;
such an exclusion would have been too restrictive with
the amount of data currently accessible.
Finally, larger clusters would also allow us to account
for and potentially exclude sequences that may be from
the same patient at different times, allowing for more
robust conclusions to be made about the genotypic
variability within a cluster. Preliminary analyses were
conducted in which one sequence each from 28
sequences pairs from the same patient in our data set
was arbitrarily excluded (even if the pair differed signifi-
cantly in genotype), yielding a 370-member set. Qualita-
tive results of genotypic variability remained similar, in
that several resistant clusters showed as much or more
genotypic diversity than randomly chosen data set mem-
bers, although again, the most resistant cluster showed a
higher percentage of shared mutations between cluster
members on average even though it now required two
representative sequences. 48 clusters were needed to
cluster the “unique-patient” data set as opposed to 50
for the original data set, suggesting that data from the
same patient taken at different time points can provide
additional phenotypic diversity. 98% of sequence pairs
grouped together in the smaller data set were grouped
together in the original data set, showing that the overall
clustering remained very similar.
Since the time the manuscript had been originally
drafted, we obtained approximately 50 more isolates,
and we have carried out very preliminary analyses of a
larger (n = 453) data set including these new sequences.
52 clusters were needed to group the data using the
same constraints with the original data set, and the phe-
notypic patterns of most clusters were identical or
highly similar; 86% of sequences pairs that had been
grouped together originally remained together in the
clustering of the larger data set. We also used our origi-
nal (n = 398) clusters to predict resistance to each drug
for each of the new isolates, using the other drugs’ resis-
tance values to select the closest centroid (i.e., the same
procedure used in the n-fold cross validation). Scaled
resistance scores (0-4) were predicted correctly from
66%-82% of the time, depending on the drug; interest-
ingly, predictions for TPV (67%) and DRV (82%) were
better than seen in the n-fold cross validation, while
those for NFV (66%) and RTV (76%) were worse. Pre-
diction accuracy may be affected by the points in time
at which the data were obtained, as resistance patterns
may change over time.
Treatment histories were not entirely available for the
current data set; acquiring such information and analyz-
ing future data in their context can provide additional
insights. For example, one could determine the extent to
which treatment histories affect the “path” seen in Fig-
ure 2 and the dependence on individual multidrug resis-
tance phenotypes on past treatment; such analyses could
highlight the extent to which treatment histories affect
the genotypic variation within a phenotypic cluster.
While the methodology and analyses were applied
here to the HIV-1 protease system, the framework is
generally applicable to any system for which there are
phenotypic data across multiple drugs. In addition to
continuing to analyze HIV-1 protease as the available
data grow, another natural next step is to apply these
methods to the HIV-1 nucleoside or non-nucleoside
reverse transcriptase inhibitor systems and to compare
the patterns of cross resistance within those systems
with the ones obtained in the present study. By rigor-
ously studying phenotypic resistance patterns of multiple
systems, one may begin to address more general ideas,
including whether cross resistance has equally affected
all target systems and whether potential genotypic diver-
sity within phenotypic clusters is a general feature of
target systems.
Conclusions
To our knowledge, this study provided the first cluster-
based analysis of the clinically-explored multidrug phe-
notypic space of HIV-1 protease, uncovering major mul-
tidrug patterns of resistance, cross resistance, and
potential hypersusceptibility. We showed that while gen-
otypic similarity implies clinical phenotypic similarity,
t h ec o n v e r s ei sn o tn e c e s s a r i l yt h ec a s e .W ea l s op r o -
vided genotypic determinants of phenotypic patterns.
Rather than consider each drug in turn, as others have
done, we have accounted for their relationships and
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Page 16 of 19collapsed the vast nine dimensional space into a smaller
one through clustering, allowing us to consider genoty-
pic features that are associated with a simultaneous
nine-drug response. We have therefore provided a new
perspective on existing drug resistance patterns and
their associated genotypic features. Such a framework
will be useful as new therapies emerge and will require
evaluation in the context of existing drug resistance.
Additional material
Additional file 1: Contains the formal integer-programming
formulations used within the work, five supplementary figures
(Figures S1-S5) and one supplementary table (Table S1). This file also
contains a link to a website containing the n = 398 data set used in this
work. (http://www.wellesley.edu/Chemistry/Radhakrishnan/projects.html).
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